Ezan E - Search Results

1

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Ménard J. Azizi M, et al. Among authors: ezan e. J Clin Invest. 1996 Feb 1;97(3):839-44. doi: 10.1172/JCI118484. J Clin Invest. 1996. PMID: 8609242 Free PMC article. Clinical Trial.

2

Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production.

Azizi M, Junot C, Ezan E, Hallouin MC, Guyene T, Ménard J. Azizi M, et al. Among authors: ezan e. J Mol Med (Berl). 2002 Aug;80(8):492-8. doi: 10.1007/s00109-002-0357-z. Epub 2002 Jun 22. J Mol Med (Berl). 2002. PMID: 12185449 Clinical Trial.

3

High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.

Azizi M, Ezan E, Nicolet L, Grognet JM, Ménard J. Azizi M, et al. Among authors: ezan e. Hypertension. 1997 Nov;30(5):1015-9. doi: 10.1161/01.hyp.30.5.1015. Hypertension. 1997. PMID: 9369248

4

Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.

Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Ménard J. Azizi M, et al. Among authors: ezan e. Hypertension. 1999 Mar;33(3):879-86. doi: 10.1161/01.hyp.33.3.879. Hypertension. 1999. PMID: 10082503 Clinical Trial.

5

Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice.

Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Capecchi M, Corvol P, Bernstein KE. Cole J, et al. Among authors: ezan e. J Clin Invest. 2000 Dec;106(11):1391-8. doi: 10.1172/JCI10557. J Clin Invest. 2000. PMID: 11104792 Free PMC article.

6

Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.

Azizi M, Junot C, Ezan E, Ménard J. Azizi M, et al. Among authors: ezan e. Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1066-9. doi: 10.1046/j.1440-1681.2001.03560.x. Clin Exp Pharmacol Physiol. 2001. PMID: 11903317

7

Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.

Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, Ezan E, Genet R, Robinson S, Briscoe T, Melville J, Riches A. Rousseau-Plasse A, et al. Among authors: ezan e. Exp Hematol. 1998 Oct;26(11):1074-9. Exp Hematol. 1998. PMID: 9766448

8

The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aorta.

Boulanger CM, Ezan E, Massé F, Mathieu E, Lévy BI, Azizi M. Boulanger CM, et al. Among authors: ezan e. Eur J Pharmacol. 1998 Dec 18;363(2-3):153-6. doi: 10.1016/s0014-2999(98)00820-6. Eur J Pharmacol. 1998. PMID: 9881583

9

In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.

Junot C, Menard J, Gonzales MF, Michaud A, Corvol P, Ezan E. Junot C, et al. Among authors: ezan e. J Pharmacol Exp Ther. 1999 Jun;289(3):1257-61. J Pharmacol Exp Ther. 1999. PMID: 10336514

10

Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.

Junot C, Nicolet L, Ezan E, Gonzales MF, Menard J, Azizi M. Junot C, et al. Among authors: ezan e. J Pharmacol Exp Ther. 1999 Dec;291(3):982-7. J Pharmacol Exp Ther. 1999. PMID: 10565814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters